Tags » Policy & Ethics

Dutch Investigation Finds Serious Flaws In Influential New England Journal Of Medicine Study

Erasmus Medical Center says it has wrapped up its investigation of Don Poldermans, the disgraced cardiology researcher who was fired for research misconduct. The full extent of the misconduct has never been known, and from an examination of the Erasmus report it appears likely that it never will be known. 69 more words

Policy & Ethics

Hormone Therapy At Menopause Fails To Halt Heart Disease Progression

More than a decade ago the Women’s Health Study produced surprising and important results when it showed that broad use of hormone replacement therapy did not reduce cardiovascular risk in post-menopausal women. 65 more words

Policy & Ethics

Death By Running: It's The Heat And Not The Heart

The growing popularity of marathons and other extreme sports has sparked worries about the potential dangers of these activities. The popular press and medical research have both focused on the risk of cardiac arrest and other heart rhythm problems. 69 more words

Policy & Ethics

Running: Any Amount Is Good And More May Not Be Better

Although there is broad agreement that exercise is beneficial there has been substantial uncertainty about how much exercise is good for you. Recently some studies have suggested that too much exercise may actually reduce the benefits of exercise. 49 more words

Policy & Ethics

More Questions Raised About Boehringer Ingelheim's Pradaxa

Once again dabigatran (Pradaxa) has raised the wrath of the critics. Several articles and an editorial published today in The BMJ raise more questions and concerns about the drug, which is the first of the new oral anticoagulants. 59 more words

Policy & Ethics

New Evidence Fuels Concerns About The Safety Of Niacin

The string of failures– for HDL therapies in general and for niacin in particular– continues unabated.  The publication of the main results of the HPS2-THRIVE trial, along with new information from the AIM-HIGH trial, provide no evidence of a beneficial effect for niacin but do fuel concerns that it may cause serious adverse effects. 11 more words

Policy & Ethics

FDA Once Again Reaches Conclusions At Odds With Its Own Staff

Once again the FDA has reached a conclusion that is directly opposed by some of its own scientists.  Last month the FDA affirmed the safety of olmesartan, a popular blood pressure lowering drug (sold as Benicar and other names). 105 more words

Policy & Ethics